close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

41.52 +0.67 (+1.64%)
Streaming Delayed Price Updated: 3:03 PM EDT, Sep 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,319,970
Open 41.76
Bid (Size) 41.49 (1,500)
Ask (Size) 41.59 (200)
Prev. Close 40.85
Today's Range 37.71 - 42.92
52wk Range 24.52 - 43.15
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved. 
Via MarketBeat
News headline image
Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗
The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off. 
Via The Motley Fool

Performance

YTD
+17.2%
+17.2%
1 Month
+24.9%
+24.9%
3 Month
+19.3%
+19.3%
6 Month
+29.1%
+29.1%
1 Year
+58.2%
+58.2%

More News

Read More
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Viking Therapeutics (NASDAQ:VKTX) Q2 Loss Beats Estimates, Shares Edge Lower as Obesity Pipeline Progresses ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing ↗
Via MarketBeat
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗
Via The Motley Fool
News headline image
Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss ↗
Via MarketBeat
News headline image
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September ↗
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗
Via The Motley Fool
News headline image
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗
Via The Motley Fool
News headline image
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong ↗
Via The Motley Fool
News headline image
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. ↗
Via The Motley Fool
News headline image
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? ↗
Via The Motley Fool
News headline image
2 GLP-1 Stocks That Could Double Your Money by 2031 ↗
Via The Motley Fool
News headline image
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? ↗
Via The Motley Fool
News headline image
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗
Via The Motley Fool
News headline image
Viking Therapeutics Stock Moves Lower: What's Going On? ↗
Via Benzinga
News headline image
Viking Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case ↗
Via The Motley Fool
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗
Via The Motley Fool

Frequently Asked Questions

Is Viking Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viking Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viking Therapeutics, Inc. - Common Stock trade on?
Viking Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viking Therapeutics, Inc. - Common Stock?
The ticker symbol for Viking Therapeutics, Inc. - Common Stock is VKTX on the Nasdaq Stock Market
What is the current price of Viking Therapeutics, Inc. - Common Stock?
The current price of Viking Therapeutics, Inc. - Common Stock is 41.52
When was Viking Therapeutics, Inc. - Common Stock last traded?
The last trade of Viking Therapeutics, Inc. - Common Stock was at 09/23/26 03:03 PM ET
What is the market capitalization of Viking Therapeutics, Inc. - Common Stock?
The market capitalization of Viking Therapeutics, Inc. - Common Stock is 4.13B
How many shares of Viking Therapeutics, Inc. - Common Stock are outstanding?
Viking Therapeutics, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.